vs
FIRST INDUSTRIAL REALTY TRUST INC（FR）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是FIRST INDUSTRIAL REALTY TRUST INC的1.1倍（$207.3M vs $194.8M），FIRST INDUSTRIAL REALTY TRUST INC净利率更高（75.9% vs -62.0%，领先137.9%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 10.0%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 8.9%）
该企业是一家房地产投资信托机构，主要投资华盛顿大都会区郊区的工业地产与商务园区类资产，拥有成熟的不动产投资运营经验，于2017年被政府物业收入信托正式收购。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
FR vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $194.8M | $207.3M |
| 净利润 | $147.9M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 75.9% | -62.0% |
| 营收同比 | 10.0% | 25.9% |
| 净利润同比 | 179.7% | 3.5% |
| 每股收益（稀释后） | $1.08 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $194.8M | — | ||
| Q4 25 | $188.4M | $207.3M | ||
| Q3 25 | $181.4M | $159.9M | ||
| Q2 25 | $180.2M | $166.5M | ||
| Q1 25 | $177.1M | $139.3M | ||
| Q4 24 | $175.6M | $164.6M | ||
| Q3 24 | $167.6M | $139.5M | ||
| Q2 24 | $164.1M | $147.0M |
| Q1 26 | $147.9M | — | ||
| Q4 25 | $78.8M | $-128.6M | ||
| Q3 25 | $65.3M | $-180.4M | ||
| Q2 25 | $55.2M | $-115.0M | ||
| Q1 25 | $48.1M | $-151.1M | ||
| Q4 24 | $68.4M | $-133.2M | ||
| Q3 24 | $99.4M | $-133.5M | ||
| Q2 24 | $51.3M | $-131.6M |
| Q1 26 | — | — | ||
| Q4 25 | 34.6% | -54.7% | ||
| Q3 25 | 37.0% | -106.9% | ||
| Q2 25 | 31.7% | -64.8% | ||
| Q1 25 | 31.2% | -102.6% | ||
| Q4 24 | 40.1% | -74.3% | ||
| Q3 24 | 62.6% | -94.6% | ||
| Q2 24 | 31.8% | -79.1% |
| Q1 26 | 75.9% | — | ||
| Q4 25 | 41.8% | -62.0% | ||
| Q3 25 | 36.0% | -112.8% | ||
| Q2 25 | 30.6% | -69.0% | ||
| Q1 25 | 27.2% | -108.5% | ||
| Q4 24 | 39.0% | -80.9% | ||
| Q3 24 | 59.3% | -95.7% | ||
| Q2 24 | 31.3% | -89.5% |
| Q1 26 | $1.08 | — | ||
| Q4 25 | $0.60 | $-1.28 | ||
| Q3 25 | $0.49 | $-1.81 | ||
| Q2 25 | $0.42 | $-1.17 | ||
| Q1 25 | $0.36 | $-1.57 | ||
| Q4 24 | $0.51 | $-1.34 | ||
| Q3 24 | $0.75 | $-1.40 | ||
| Q2 24 | $0.39 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $-80.0M |
| 总资产 | $5.8B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $78.0M | $421.0M | ||
| Q3 25 | $33.5M | $202.5M | ||
| Q2 25 | $34.9M | $176.3M | ||
| Q1 25 | $35.7M | $127.1M | ||
| Q4 24 | $44.5M | $174.0M | ||
| Q3 24 | $47.1M | $150.6M | ||
| Q2 24 | $38.5M | $480.7M |
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.7B | $-80.0M | ||
| Q3 25 | $2.7B | $9.2M | ||
| Q2 25 | $2.6B | $151.3M | ||
| Q1 25 | $2.7B | $144.2M | ||
| Q4 24 | $2.7B | $255.0M | ||
| Q3 24 | $2.6B | $346.8M | ||
| Q2 24 | $2.6B | $432.4M |
| Q1 26 | $5.8B | — | ||
| Q4 25 | $5.7B | $1.5B | ||
| Q3 25 | $5.5B | $1.2B | ||
| Q2 25 | $5.5B | $1.3B | ||
| Q1 25 | $5.4B | $1.3B | ||
| Q4 24 | $5.3B | $1.5B | ||
| Q3 24 | $5.2B | $1.5B | ||
| Q2 24 | $5.2B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $461.3M | $-99.8M | ||
| Q3 25 | $124.6M | $-91.4M | ||
| Q2 25 | $126.1M | $-108.3M | ||
| Q1 25 | $88.6M | $-166.5M | ||
| Q4 24 | $352.5M | $-79.3M | ||
| Q3 24 | $105.5M | $-67.0M | ||
| Q2 24 | $107.7M | $-77.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 5.85× | — | ||
| Q3 25 | 1.91× | — | ||
| Q2 25 | 2.28× | — | ||
| Q1 25 | 1.84× | — | ||
| Q4 24 | 5.15× | — | ||
| Q3 24 | 1.06× | — | ||
| Q2 24 | 2.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FR
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
